Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Abroad (travel likely)RecruitingPHASE2
Conditions
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0) · Albuminuria
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Illinois Chicago, Sickle Cell Center, Chicago, Illinois, United States
Contact: Study coordinator (Anand Srivastava, MD)